Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia
Chronic Lymphocytic Leukemia
DRUG: Bendamustine hydrochloride injection|DRUG: Chlorambucil
Objective Response Rate (ORR), after 3 cycles and 6 cycles
Progression-free Survival (PFS), December 2013|Duration of Remission (DR), December 2013|Overall Survival (OS), December 2013|The incidence and severity of adverse events, Up to 2 years after enrollment
Patients will be assessed for response after three cycles of treatment. Two additional cycles are recommended for CR, PR or SD patients, up to a maximum limit of six cycles in total. Patients will be followed up every three months until disease progression or death.